Wegovy real results: separating the clinical evidence from the hype

The myth that Wegovy works the same way for everyone

A number that travels fast on social media is the 15% average. Averages are useful; they are also misleading if you treat them as a personal forecast. In the STEP 1 trial, the range of responses was wide. Some participants lost well over 20% of their body weight by week 68. Others, responding less strongly, lost closer to 5–8%. Both groups were taking the same medicine at the same dose alongside the same lifestyle programme.

Several factors shape where an individual lands in that range: how long someone has lived with obesity, whether they have type 2 diabetes (in a separate trial, STEP 2, average loss in people with diabetes was closer to 10%), how well GI side effects are tolerated during titration, and how consistently lifestyle changes are maintained. The trial measured outcomes at 68 weeks; weight regain after stopping is also documented in the evidence. That is not a reason to avoid treatment, it is a reason to approach it as a long-term health strategy, discussed properly with a prescriber, rather than a short-term fix.

You can read a fuller breakdown of the trial data on our Wegovy clinical trial results page, which covers STEP 1 through to the cardiovascular outcome data.

What the 7.2mg approval actually changes about the results picture

For years the comparison between Wegovy and Mounjaro (tirzepatide) pointed in one direction: the SURMOUNT-5 head-to-head trial, published in 2025, found tirzepatide produced greater average weight reduction than semaglutide 2.4mg over 72 weeks. That gap was real and clinically meaningful.

The MHRA's approval of a higher 7.2mg semaglutide dose (first in January 2026, then the single-dose pen on 14 April 2026) changes the comparison somewhat. Trials at 7.2mg reported around 20.7% average weight loss over 72 weeks, putting it much closer to tirzepatide's highest-dose results. The 7.2mg pen is licensed for adults with a BMI of 30 or above; it is not automatically the right starting point, and the titration path still begins at 0.25mg. The MHRA announcement of the 7.2mg pen approval has the exact licensing detail.

Which dose (and which medicine) suits a particular person is a clinical question. Our Wegovy overview explains both the injection and the newer oral tablet option for anyone comparing routes.

The lifestyle factor the results pages usually bury

Every participant in STEP 1 was enrolled in a structured lifestyle programme: regular dietary counselling, a reduced-calorie plan, and an increase in physical activity. The 15% average was achieved within that context, not despite it. Studies looking at semaglutide without active lifestyle support tend to show more modest effects.

In practical terms, this means the medicine is doing its job (reducing appetite, slowing gastric emptying, making it significantly easier to sustain a calorie deficit) but it works with your efforts, not instead of them. Protein intake, hydration, and some form of regular movement matter more on treatment, not less, because appetite suppression can make it easy to under-eat in ways that cause muscle loss. Keeping the pen in the same place each week (the fridge door works for most people) helps build the routine that supports all of this.

Our page on getting the best results on Wegovy goes into the lifestyle side in detail, including what the clinical guidance says about diet and activity alongside treatment. For the semaglutide-specific version of that advice, the semaglutide results guide is worth reading alongside it.

How to approach real results as a prospective patient

Wegovy is a licensed, prescription-only medicine for weight management. NICE's appraisal of semaglutide (TA875) sets out the population in which the evidence is strongest: adults with a BMI of 35 or above (or 30–34.9 meeting specialist-referral criteria) and at least one weight-related condition, used alongside specialist-level support. Those thresholds are lower (by around 2.5 kg/m²) for people from South Asian, Chinese, Middle Eastern, Black African or African-Caribbean backgrounds.

Private prescribing follows the licensed criteria set out in the medicine's SmPC, which allows broader access than the NICE-recommended NHS route. A prescriber looks at the full picture: your BMI, your health history, any medicines you already take, and whether Wegovy, Mounjaro, or the newer oral semaglutide tablet is the more appropriate option. Real results, for any individual, begin with that assessment, not with the trial average.

If you are looking at costs and want to understand what a private prescription typically includes, our guide to getting Wegovy in the UK covers the access route, what legitimate private prescribing looks like, and what to watch for if you come across prices that seem far below the market. When you are ready to have your situation reviewed by one of our GPhC-registered prescribers, you can start your free consultation, a real clinician reads your answers the same day.